4.1.4.2.4. oestrogens. oestrogen treatment ui tested using oral, transdermal, vaginal routes administration. vaginal (local) treatment primarily used treat symptoms vaginal atrophy postmenopausal women. available evidence related mainly sui, although reviews include participants uui, difficult generalise results women predominantly oab/uui. association luts genitourinary syndrome menopause (gsm) considered . genitourinary syndrome menopause new term describes various menopausal symptoms signs associated physical changes vulva, vagina lut. include mucosal pallor/erythema, loss vaginal rugae, tissue fragility/fissures, vaginal petechiae, urethral mucosal prolapse, introital retraction vaginal dryness. evidence sr suggest benefit vaginal oestrogen therapy gsm . vaginal oestrogens demonstrated superiority objective subjective end points gsm compared placebo. trials demonstrated superiority vs. placebo urogenital symptoms (ui, recurrent uti, urgency, frequency). significant difference observed various doses dosage forms vaginal oestrogen products. vaginal oestrogen showed superiority vaginal lubricants moisturisers improvement objective clinical end points vulvovaginal atrophy subjective end points . available evidence suggests vaginal treatment oestradiol oestriol associated increased risk thromboembolism, endometrial hypertrophy, breast cancer seen systemicadministration [236-238].